The Westin Paris-Vendôme
3 Rue De Castiglione
Paris, 75001, France
Tel: +33 (0) 1 44 77 11 11
Hotel Information Link
How do you assimilate the recent advances for the treatment of lymphoid malignancies and apply them to your patients? It is a challenge. What is great news for the field also adds to the complexity of managing these malignancies in real-world practice settings.
Our ability to characterize tumors, stratify risk, and manage lymphoid malignancies continues to evolve at a rapid pace. Sophisticated molecular techniques, which are used to individualize risk stratification and guide treatment, as well as novel targeted and immunotherapeutic options has expanded the treatment armamentarium in the field. The fast pace at which practice-changing evidence continues to emerge poses a constant challenge for clinicians to maintain cutting-edge practice in managing patients with these tumors. Although optimized outcomes depend on the incorporation of novel strategies and proactive mitigation of predictable treatment-related adverse events, it is essential that practitioners have the ability to contextualize landmark trial findings and apply them to their patients.
The 2nd Annual European Congress on Hematology™: Focus on Lymphoid Malignancies is a highly practical and interactive multi-day program that will improve patient care for the clinician who manages patients with lymphoid malignancies. The exciting case-based format is back by popular demand at this year’s Congress, where leading international experts will participate in informative lectures and panels that will discuss recent data sets. What sets this meeting apart are the interactive discussions at the Congress where participants will be challenged to engage directly with renowned faculty to share their perspectives, personal experiences, and methods to address clinical challenges in the management of lymphoid malignancies.
This educational activity is directed toward healthcare professionals who practice primarily outside of the United States. It is specifically designed for medical oncologists and other healthcare professionals (physicians, physicians-in-training, oncology nurses, pharmacists, physicians' assistants, etc.) involved in the treatment and management of patients with hematologic malignancies.
At the conclusion of this activity, you should be better prepared to:
Anas Younes, MD
Professor and Chief, Lymphoma Service
Division of Hematologic Oncology
Memorial Sloan Kettering Cancer Center
New York, New York, USA
Paolo Ghia, MD, PhD
Università Vita-Salute San Raffaele
Director, Strategic Research Program on CLL
IRCCS San Raffaele Scientific Institute
Gilles A. Salles, MD, PhD
Université Claude Bernard Lyon- 1
Hospices Civils de Lyon
Véronique LeBlond, MD
Head of the Department of Hematology
Marek Trneny, MD, CSc
Professor Medical Oncology
Ist Department of Medicine
Charles University General Hospital
Prague, Czech Republic
Dec 31, 2018
Medical Crossfire®: Defining New Roles for the Application of PARP Inhibition Strategies in Multiple Tumor Types
Dec 31, 2018
Dec 31, 2018